L Rojas
Overview
Explore the profile of L Rojas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
701
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Diaz de la Osa A, Almenares Casanova M, Fernandez Millares B, Aguado Casas M, Rojas L, Zeilinger S, et al.
Fungal Biol
. 2025 Jan;
129(1):101530.
PMID: 39826978
The aim of this work is to evaluate different molecular strategies deployed by indigenous isolates of Trichoderma in their interaction with the phytopathogen Botrytis cinerea. In vitro antagonism assays, determination...
2.
Rojas L, Mayorga D, Ruiz-Patino A, Rodriguez J, Cardona A, Archila P, et al.
ESMO Open
. 2022 Jun;
7(4):100500.
PMID: 35753086
Background: Human papilloma virus (HPV) has been associated with the development and modulation of response in a series of neoplasms. In the case of lung adenocarcinoma, its role in etiology...
3.
Giesbrecht G, Rojas L, Patel S, Kuret V, MacKinnon A, Tomfohr-Madsen L, et al.
J Affect Disord
. 2021 Dec;
299:483-491.
PMID: 34952107
Background: Sustained fear during pregnancy has the potential to increase psychological distress and obstetric risk. This study aimed to (1) identify factors and characteristics associated with fear of COVID-19, (2)...
4.
Arenas A, Serrano C, Quinones L, Harris P, Sandoval M, Lavanderos M, et al.
Sci Rep
. 2019 Dec;
9(1):20070.
PMID: 31882676
Helicobacter pylori (H. pylori) eradication using standard triple therapy (STT) with proton pump inhibitors (PPI), amoxicillin and clarithromycin (CLA) has been the standard in Latin America. However, CLA resistance is...
5.
Figueroa R, Rojas L, Valente M
Appl Radiat Isot
. 2019 Jun;
151:13-18.
PMID: 31153053
Convergent beam radiotherapy, or CBRT, currently under development is based on the adaptation of a linear accelerator (linac) to a device which allows to dynamically curve the original trajectory of...
6.
Cardona A, Rojas L, Wills B, Ruiz-Patino A, Abril L, Hakim F, et al.
Clin Transl Oncol
. 2019 Feb;
21(10):1364-1373.
PMID: 30798512
Purpose: Patients with recurrent glioblastoma (rGBM) have a poor prognosis, with survival ranging from 25 to 40 weeks. Antiangiogenic agents are widely used, showing a variable response. In this study,...
7.
Monasterio G, Castillo F, Rojas L, Cafferata E, Alvarez C, Carvajal P, et al.
J Oral Rehabil
. 2018 May;
45(8):589-597.
PMID: 29761933
It is well accepted that the presence of cytokines belonging to the Th1/Th17/Th22 axis of immuno-inflammatory response in the joint environment, such as IL-1β, IL-17 and IL-22, respectively, are associated...
8.
Figueroa R, Leiva J, Moncada R, Rojas L, Santibanez M, Valente M, et al.
Appl Radiat Isot
. 2018 Mar;
141:187-192.
PMID: 29555377
Conventional radiotherapy is mainly applied by linear accelerators. Although linear accelerators provide dual (electron/photon) radiation beam modalities, both of them are intrinsically produced by a megavoltage electron current. Modern radiotherapy...
9.
Megias-Vericat J, Montesinos P, Herrero M, Moscardo F, Boso V, Rojas L, et al.
Pharmacogenomics J
. 2017 May;
18(2):301-307.
PMID: 28485375
Efficacy and toxicity of anthracycline treatment in acute myeloid leukemia (AML) is mediated by reactive oxygen species (ROS). NADPH oxidase is the major endogenous source of ROS and a key...
10.
Diaz-Zuniga J, Melgar-Rodriguez S, Rojas L, Alvarez C, Monasterio G, Carvajal P, et al.
J Periodontal Res
. 2017 Apr;
52(5):893-902.
PMID: 28393368
Background And Objective: Two new T-helper (Th) phenotypes have been recently described and named Th9 and Th22 lymphocytes; however, their role in the pathogenesis of periodontitis remains unclear. This study...